UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Rule 13d-101)
INFORMATION TO BE INCLUDED
IN STATEMENTS FILED PURSUANT
TO § 240.13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO
§ 240.13d-2(a)
(Amendment No. 2)1
Heron Therapeutics, Inc.
(Name
of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
427746102
(CUSIP Number)
Rubric Capital Management LP
155 East 44th St, Suite 1630
New York, New York 10017
Attention: Brian Kleinhaus
(212) 418-1888
Ryan Nebel
Olshan Frome Wolosky LLP
1325 Avenue of the Americas
New York, New York 10019
(212) 451-2300
(Name, Address and Telephone Number of Person
Authorized to Receive Notices
and Communications)
July 21, 2023
(Date of Event Which Requires
Filing of This Statement)
If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box ¨.
Note: Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See
§ 240.13d-7 for other parties to whom copies are to be sent.
1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
NAME OF REPORTING PERSON |
|
|
|
|
|
|
|
|
|
|
Rubric Capital Management LP |
|
|
2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ☐ |
|
|
|
|
(b) ☐ |
|
|
|
|
|
|
|
3 |
|
SEC USE ONLY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4 |
|
SOURCE OF FUNDS |
|
|
|
|
|
|
|
|
|
|
AF |
|
|
5 |
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) |
☐ |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
|
|
|
|
|
|
|
|
DELAWARE |
|
NUMBER OF |
|
7 |
|
SOLE VOTING POWER |
|
SHARES |
|
|
|
|
|
BENEFICIALLY |
|
|
|
|
- 0 - |
|
OWNED BY |
|
8 |
|
SHARED VOTING POWER |
|
EACH |
|
|
|
|
|
REPORTING |
|
|
|
|
26,713,503 |
|
PERSON WITH |
|
9 |
|
SOLE DISPOSITIVE POWER |
|
|
|
|
|
|
|
|
|
|
|
|
- 0 - |
|
|
|
10 |
|
SHARED DISPOSITIVE POWER |
|
|
|
|
|
|
|
|
|
|
|
|
26,713,503 |
|
|
11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
|
|
|
|
|
|
|
26,713,503 |
|
|
12 |
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |
☐ |
|
|
|
|
|
|
|
|
|
|
|
|
13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
|
|
|
|
|
|
|
|
|
|
19.0% |
|
|
14 |
|
TYPE OF REPORTING PERSON |
|
|
|
|
|
|
|
|
|
|
PN, IA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
NAME OF REPORTING PERSON |
|
|
|
|
|
|
|
|
|
|
David Rosen |
|
|
2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP |
(a) ☐ |
|
|
|
|
(b) ☐ |
|
|
|
|
|
|
|
3 |
|
SEC USE ONLY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4 |
|
SOURCE OF FUNDS |
|
|
|
|
|
|
|
|
|
|
AF |
|
|
5 |
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) |
☐ |
|
|
|
|
|
|
|
|
|
|
|
|
6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
|
|
|
|
|
|
|
|
USA |
|
NUMBER OF |
|
7 |
|
SOLE VOTING POWER |
|
SHARES |
|
|
|
|
|
BENEFICIALLY |
|
|
|
|
- 0 - |
|
OWNED BY |
|
8 |
|
SHARED VOTING POWER |
|
EACH |
|
|
|
|
|
REPORTING |
|
|
|
|
26,713,503 |
|
PERSON WITH |
|
9 |
|
SOLE DISPOSITIVE POWER |
|
|
|
|
|
|
|
|
|
|
|
|
- 0 - |
|
|
|
10 |
|
SHARED DISPOSITIVE POWER |
|
|
|
|
|
|
|
|
|
|
|
|
26,713,503 |
|
|
11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
|
|
|
|
|
|
|
26,713,503 |
|
|
12 |
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |
☐ |
|
|
|
|
|
|
|
|
|
|
|
|
13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
|
|
|
|
|
|
|
|
|
|
19.0% |
|
|
14 |
|
TYPE OF REPORTING PERSON |
|
|
|
|
|
|
|
|
|
|
IN |
|
The following constitutes
Amendment No. 2 to the Schedule 13D filed by the undersigned (“Amendment No. 2”). This Amendment No. 2 amends the Schedule
13D as specifically set forth herein.
| Item 3. | Source and Amount of Funds or Other Consideration. |
Item 3 is hereby amended
and restated to read as follows:
The Shares reported herein
beneficially owned by Rubric Capital were purchased with the working capital of the Rubric Funds (which may, at any given time, include
margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of the 26,713,503 Shares beneficially
owned by Rubric Capital is approximately $60,623,900, including brokerage commissions.
| Item 4. | Purpose of Transaction. |
Item 4 is hereby amended
to add the following:
On July 21, 2023, Rubric
Capital entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private
Placement”) with the Issuer and certain other purchasers. Pursuant to the Purchase Agreement, Rubric Capital agreed, on behalf of
certain of the Rubric Funds, to purchase 14,963,503 Shares at a price of $1.37 per Share. The Private Placement closed on July 25, 2023.
The Purchase Agreement provides
that the Issuer will register the resale of the Shares. The Issuer is required to prepare and file a registration statement with the Securities
and Exchange Commission no later than August 24, 2023, and to use its commercially reasonable efforts to have the registration statement
declared effective as soon as practicable, subject to certain specified penalties if timely effectiveness is not achieved. The Purchase
Agreement also provides the purchasers participation rights in future offerings conducted by the Issuer during the period from the closing
date through and including the fifth year anniversary of the closing date, subject to certain exceptions.
In connection with the Private
Placement, the Issuer provided a waiver under the Cooperation Agreement (as defined in Amendment No. 1 to the Schedule 13D) with respect
to the standstill provision that would have prevented the aggregate beneficial ownership of the Investor Group (as defined in the Cooperation
Agreement) from exceeding 15.0% of the outstanding Shares.
The foregoing description
of the Purchase Agreement is qualified in its entirety by reference to the full text of the Purchase Agreement, which is included as Exhibit
99.1 hereto and is incorporated by reference herein.
| Item 5. | Interest in Securities of the Issuer. |
Items 5(a) – (c) are
hereby amended and restated to read as follows:
(a) The
aggregate percentage of Shares reported owned by each person named herein is based upon 140,759,276 Shares believed to be outstanding
as of July 25, 2023 following the closing of the Private Placement, consisting of the (i) 120,024,359 Shares outstanding as of July 21,
2023 as reported in Exhibit 10.1 to the Issuer’s current report on Form 8-K filed with the Securities and Exchange Commission on
July 24, 2023, and (ii) 20,734,917 Shares believed to be issued in connection with the closing of the Private Placement.
As of the date hereof, Rubric
Capital and Mr. Rosen may be deemed to beneficially own the 26,713,503 Shares, constituting approximately 19.0% of the Shares outstanding,
held in the aggregate by the Rubric Funds.
The filing of this Schedule
13D shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Exchange Act, the beneficial
owners of any securities of the Issuer he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial
ownership of the securities reported herein that he or it does not directly own.
(b) Each
of Rubric Capital and Mr. Rosen may be deemed to share the power to vote and dispose of the Shares held by the Rubric Funds.
(c) Other
than in connection with the Private Placement described in Item 4 above, there have been no transactions in securities of the Issuer by
the Reporting Persons during the past 60 days. On July 21, 2023, pursuant to the Purchase Agreement, Rubric Capital agreed, on behalf
of certain of the Rubric Funds, to purchase 14,963,503 Shares at a price of $1.37 per Share.
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer. |
Item 6 is hereby amended
to add the following:
The disclosure with respect
to the Private Placement set forth in Item 4 above, including the description of the Purchase Agreement and the waiver to the Cooperation
Agreement granted by the Issuer, is incorporated herein by reference.
| Item 7. | Material to be Filed as Exhibits. |
Item 7 is hereby
amended to add the following exhibit:
| 99.1 | Securities Purchase Agreement, dated as of July 21, 2023 (incorporated herein by reference to Exhibit
10.1 of the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 24, 2023). |
SIGNATURES
After reasonable inquiry
and to the best of his or its knowledge and belief, the undersigned certifies that the information set forth in this statement is true,
complete and correct.
Dated: July 25, 2023
|
Rubric Capital Management LP |
|
|
|
By: |
Rubric Capital Management GP LLC
General Partner |
|
|
|
By: |
/s/ David Rosen |
|
|
Name: |
David Rosen |
|
|
Title: |
Managing Member |
|
/s/ David Rosen |
|
David Rosen |
Heron Therapeautics (NASDAQ:HRTX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Heron Therapeautics (NASDAQ:HRTX)
Gráfica de Acción Histórica
De May 2023 a May 2024